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Chromosome 1 is involved in quantitative anomalies in 50–60% of breast tumours. However, the structure of these anomalies and
the identity of the affected genes remain to be determined. To characterise these anomalies and define their consequences on gene
expression, we undertook a study combining array-CGH analysis and expression profiling using specialised arrays. Array-CGH data
showed that 1p was predominantly involved in losses and 1q almost exclusively in gains. Noticeably, high magnitude amplification was
infrequent. In an attempt to fine map regions of copy number changes, we defined 19 shortest regions of overlap (SROs) for gains
(one at 1p and 18 at 1q) and of 20 SROs for losses (all at 1p). These SROs, whose sizes ranged from 170kb to 3.2Mb, represented
the smallest genomic intervals possible based on the resolution of our array. The elevated incidence of gains at 1q, added to the well-
established concordance between DNA copy increase and augmented RNA expression, made us focus on gene expression changes
at this chromosomal arm. To identify candidate oncogenes, we studied the RNA expression profiles of 307 genes located at 1q using
a home-made built cDNA array. We identified 30 candidate genes showing significant overexpression correlated to copy number
increase. In order to substantiate their involvement, RNA expression levels of these candidate genes were measured by quantitative
(Q)-RT–PCR in a panel of 25 breast cancer cell lines previously typed by array-CGH. Q–PCR showed that 11 genes were
significantly overexpressed in the presence of a genomic gain in these cell lines, and 20 overexpressed when compared to normal
breast.
British Journal of Cancer (2006) 95, 1439–1447. doi:10.1038/sj.bjc.6603433 www.bjcancer.com
Published online 24 October 2006
& 2006 Cancer Research UK
Keywords: array-CGH; amplicon; oncogene; profiling
                                                       
Chromosome 1 is recurrently altered in a number of human
malignancies. In solid tumours, structural aberrations include
several recurrent chromosomal translocation sites, as well as
frequent gains or losses involving either chromosomal arm
(Struski et al, 2002; Teixeira et al, 2002). In breast cancer,
chromosome 1 is the site of rare stereotypic rearrangements;
isochromosome i(1)(q10), and der(1;16)(q10;p10) (Tsarouha et al,
1999). More significantly, it has been shown, by either LOH or
CGH work, to be frequently involved in copy number changes
(CNCs) (Kerangueven et al, 1997; Osborne and Hamshere, 2000).
Fifty to 60% of breast tumours analysed by CGH presented gains at
1q, whereas the short arm showed predominantly losses, except the
1p31–p32 region which presented occasional gains (Courjal and
Theillet, 1997; Tirkkonen et al, 1998). Gains at 1q frequently affect
the whole arm; however, a number of tumours or cell lines exhibit
interstitial gains sometimes reduced to a chromosomal band or
sub-band (Courjal and Theillet, 1997; Larramendy et al, 2000).
These data suggesting the existence at 1q of several regions of
gains were thus concordant with LOH studies, indicating the
occurrence of at least four regions of allelic imbalance in breast
tumours (Kerangueven et al, 1997). Because gains at 1q were
observed both in low- and high-grade breast tumours, its
implication in early stages of disease development has been shown
(Tirkkonen et al, 1998; Cummings et al, 2000). Recent data using
BAC-based array-CGH on independent sets of breast tumours have
confirmed the frequent nature of gains on chromosome 1, as well
as the existence of multiple cores of amplification (Stange et al,
2006).
Altogether, these data suggested the presence of several
important cancer genes on chromosome 1. Several known
oncogenes (NRAS, JUN, MYCL, TAL1, BLYM, LCK) map on
chromosome 1q, but their implication in breast cancer has
remained elusive, whereas genes like MUC1 and PLU-1/JARIB1
were proposed as candidates (Bieche et al, 1997; Lu et al, 1999).
However, it seems clear that most genes involved remain to be
identified. This notion was reinforced by recent expression
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located on the long arm of chromosome 1 showed increased
expression levels in conjunction to DNA copy number increase
(CNI) (Hyman et al, 2002).
Our goal in this work was to determine more precisely the
boundaries of regions of chromosome 1 showing CNCs in breast
tumours and gain insight on genes involved. To achieve this, we
built a genomic array covering both arms of chromosome 1 at an
average density of one BAC clone/0.85Mb and analysed 30 breast
cancer cell lines and 30 primary breast tumours by array-CGH.
Based on the array-CGH profile, we defined shortest regions of
overlap (SROs) of copy number gain or loss. A total of 20 regions
of loss, all located at chromosome 1p, and 19 regions of gain, one
at 1p and 18 at 1q, were defined. Because gains at 1q were found in
over 60% of the analysed samples and increased copy number are
clearly related to augmented gene expression, we focused our
expression study on the identification of candidate genes at 1q. To
this aim, we studied expression profiles of 307 known genes
located on the long arm of chromosome 1. Using a supervised
analysis method, we selected 30 genes showing significantly
increased RNA expression in relation to genomic gains. RNA
expression levels of 28 out of 30 genes were verified by quantitative
(Q)–RT–PCR and the overexpression in relation to gains was
confirmed for 11 out of 28 genes, whereas 20 out of 28 showed
overexpression compared to normal breast.
MATERIALS AND METHODS
Tumours and blood samples
Thirty breast tumours were obtained from the Pathology Depart-
ment at the Val d’Aurelle Cancer Center of Montpellier (France).
Tumour biopsies were snap-frozen in liquid nitrogen upon
surgical removal and stored at  801C until DNA and RNA
extraction. Tumour cohort was composed of 63.7% invasive ductal
carcinoma, 18% invasive lobular carcinoma, 15% invasive
adenocarcinoma of unspecified type and 3.3% other types of
carcinomas of the breast. The mean age of patients was 58 years.
Tumours were mostly grade 2 and 3 (46.7 and 29.2%, respectively),
whereas 13.9% were grade 1 and 10% were uninformed.
Cell lines and tumours
Breast cancer cell lines used in this study included BRCAMZ01,
MDAMB175, MDAMB453 (D Birnbaum, INSERM U119, Marseille,
France), CAL51, MDAMB435, SKBR7, ZR7530 (P Edwards, Depart-
ment of Pathology, Cambridge, UK), BT474, MCF7Rich (F Vignon,
INSERM U540, Montpellier, France), HS578T, MDAMB436, (A
Puisieux, INSERM U590, Lyon, France), SUM149, SUM185, SUM52
(S Ethier, University of Michigan, Ann Arbor, MI, USA), EFM19,
(DSMZ, Braunschweig – Germany), BT20, BT483, HCC1187,
HCC1395, HCC1428, HCC1937, HCC1954, HCC2218, MDAMB157,
MDAMB361, MDAMB468, SKBR3, T47D, UACC812 and ZR751
(ATCC, American Type Culture Collection, Manassas, VA, USA).
All cell lines were cultured as recommended by suppliers.
Genomic arrays
We built a genomic array covering chromosomes 1, 8 and 17.
Coverage of chromosomes 8 and 17 has been described by Orsetti
et al (2004) and Gelsi-Boyer et al (2005). Chromosome 1 was
covered by 257 BAC clones selected as follows: 225 BAC clones
from the Barbara Trask collection (CHORI) http://www.ncbi.nlm.
nih.gov/genome/cyto/hbrc.shtml and 32 clones selected according
to their cytogenetic position and content in genetic markers.
Clones were arranged according to the human genome freeze of
April 2003. This resulted in an average density of one clone/
0.85Mb70.95Mb. However, clone distribution was uneven and
thus could produce local variations in resolution (a complete list of
BAC clones with precise coordinates is available in Supplementary
Table S1).
Arrays were produced according to the following procedure.
BAC, PAC and Cosmid DNA were isolated using Nucleobond
BAC100 from Macherey-Nagel (Hoerdt, France). Probe DNA to be
spotted was prepared by DOP-PCR amplification on 10ng of BAC
matrix DNA in a final reaction volume of 100ml. Primer sequences
and DOP-PCR protocol used are available on the Sanger Center
web site (http://www.sanger.ac.uk/HGP/methods/cytogenetics/
DOPPCR.shtml) (Orsetti et al, 2004). We performed this with
slight modifications: the second round DOP-PCR primer was not
aminolinked. Purification of PCR products was carried out using
Nucleofast 96 PCR plates (Macherey-Nagel, Hoerdt, France).
Purified PCR products were re-suspended in dd H2Oa t2mgml
 1.
An aliquot was run on an agarose gel in order to ascertain even
distribution of the product in all the wells. Prior spotting products
were diluted 1:1 in spotting solution (GE-Healthcare, Orsay,
France) and spotted in quadriplicate onto Corning GapsII slides
(Schiphol-Rijk, The Netherlands) using a Lucidea array spotter IV
(Amersham Biosciences, Orsay, France).
Array-CGH probe labelling, hybridisation, image capture
and data analysis
Genomic DNA was digested by NdeII according to the supplier’s
recommendations (Roche Diagnostics, Meylan, France). Three
hundred nanograms of digested genomic DNA was labelled by
random priming in a 50ml reaction containing 0.02mM dATP,
0.02mM dGTP, 0.02mM dTTP, 0.05mM dCTP, 0.04mM Cy3-dCTP
or Cy5-dCTP, 25U of Klenow Fragment (50Uml
 1, New England
Biolabs, Ozyme, Saint Quentin Yvelines, France), 10mM -
mercaptoethanol, 5mM MgCl2,5 0 m M Tris-HCL (pH 6.8) and
300mgml
 1 random octamers. The reaction was incubated at 371C
for 20h and stopped by adding 2.5ml EDTA 0.5 M pH 8. The
reaction product size was about 100bp. We purified labelled
products using microcon 30 filters (Amicon, Millipore, Molsheim,
France). Abundance of the labelled DNA was checked using a
spectrophotometer and incorporation of dyes was calculated using
Molecular Probes software (http://www.probes.com/resources/
calc/basedyeratio.html). A mix of 700pmol Cy5- and 700pmol
Cy3-labelled probes was ethanol-precipitated in the presence of
250–300mg of human Cot-1 DNA (Roche Diagnostics, Meylan,
France) and 100mg herring sperm DNA (Promega, Charbonnie `res,
France). The pellet was dried and re-suspended in 110ml Hybrisol
VII (Appligene Oncor, Qbiogen, Illkirch, France). The probes were
denatured at 801C for 10min, and repetitive sequences were
blocked by pre-annealing at 371C for 30min.
Slide processing was performed using a HS4800 hybridisation
station (Tecan, Lyon, France). Slides were treated with a blocking
buffer (5  SSC, 0.2% SDS, 1% BSA) at 421C for 30min and
washed three times at 421C using 2  SCC, 0.2% SDS. Pre-
annealed probes were injected in the chambers and hybridisation
took place at 371C for 16h with mild agitation. Post-hybridisation
washes were as follows: three washes at 52.51C in solution 1 (2 
SSC, 0.2% SDS), followed by three washes in solution 2 (0.5  SSC,
0.2% SDS) and one wash in solution 3 (0.1  SSC) at 52.51C. To
remove salt and detergent residues, a brief wash with dd water was
performed at 371C and slides were dried within the chambers by an
injection of N2 at 301C.
Arrays were scanned by a GenIII Array Scanner (Amersham
Biosciences, Orsay, France). Images were analysed by ARRAY-
VISION 6.0 software (Amersham Biosciences, Orsay, France).
Spots were defined by use of the automatic grid feature of the
software and manually adjusted when necessary. Fluorescence
intensities of all spots were then calculated after subtraction of
local background. These data were then analysed using a custom
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normalised with the entire set of spots on the array, Cy3/Cy5 ratios
were calculated, each BAC clone was spotted in four replicates, the
median values of replicate spots were calculated and these values
were used to define the selection threshold for individual spots.
Only replicates showing less than 15% of deviation from the
median were kept and a clone was taken into consideration when
at least three of four replicates showed values within the 15%
deviation limit. Representation of profiles with log2 ratios in Y-
axis and Mb position of clones (http://genome.ucsc.edu, April 2003
freeze) along the chromosome in X-axis. For each sample, at least
two experiments were performed (Cy3/Cy5 and Cy5/Cy3), and the
final profile corresponds to the mean of two experiments.
RNA expression profiling of chromosome 1q using cDNA
arrays
Variations in gene expression levels were analysed by large-scale
measurement with home-made cDNA mini-arrays (7.5 9cm; 720
human genes; 11 genescm
 2) produced as described (Nugoli et al,
2003). More specifically, our mini-arrays comprised 319 ESTs
corresponding to 307 known genes mapping at 1q (Supplementary
Table S2). Selection of cDNA clones was performed according to
information gathered (and crosschecked) from different web-
based databases; Genemap: http://www.ncbi.nlm.nih.gov/gene-
map99/, Genecards: http://genecards.weizmann.ac.il/, Genelynx:
http://www.genelynx.org/ or UCSC Genome Browser, release April
2003: http://genome.ucsc.edu/. Hybridisation signals were quanti-
fied using the HDG Analyzer software (Genomic Solutions, Ann
Arbo, MI, USA) by integrating all spot pixel signal intensities and
removing spot background values determined in the neighbouring
area.
Quantitative RT–PCR
RNAs from cell lines and normal breast samples used for real-time
PCR were isolated using the RNeasy Minikit (Qiagen, France) in
accordance with the supplier’s conditions. 1mg of total RNA,
treated beforehand with RNase-free DNase (Promega, France), was
reverse-transcribed using the SuperScript II RT and 250ng of
random hexamers (Invitrogen, France). Q–PCR reactions were
carried out in an ABI Prism 7000 instrument (Applied Biosystems,
France) in a final volume of 15ml according to the supplier’s
recommendations using SYBR Green as a detector. Primers were as
described in Supplementary Table S3 in the supplementary data.
We designed the primers for 17 genes, with the assistance of the
Primer Express software (Applied Biosystems, France), and for
the remaining 14 we used the Quantitect Primer Assays from the
Gene Globe database (Qiagen, France). ESRRG primers were as
described by Ariazi et al (2002). Standard curves were determined
for each gene analysed by the use of serial dilutions from the same
pool of cDNAs. Relative quantities were calculated referring to
these curves and relative expression levels of each target gene was
normalised to 28S RNA.
Identification of aberrantly expressed genes in regions of
CNC
We applied a supervised analysis scheme to identify genes
significantly correlated to CNCs. Sample selection was based on
array-CGH profiles. For each consensus region, samples presenting
at least 25% of the BACs included in the region with log2 ratio
exceeding 0.25 were considered as amplified. For each available
gene at 1q, we computed a discriminating score (DS) by comparing
expression levels between the subgroup of samples presenting
amplification (subgroup 1) and the subgroup of samples without
amplification (subgroup 2). Discriminating score (Golub et al,
1999) was defined as DS¼(M1 M2)/(S1þS2), where M1 and S1
represent mean and the s.d. of expression levels of one gene in
subgroup 1, M2 and S2 in subgroup 2. Confidence levels were
calculated by performing 1200 iterative random permutations per
gene as described previously (Bertucci et al, 2004). Significance
threshold for expression differences was DSX0.32 corresponding
to o0.01 false positive. For Q–PCR results, we applied a t-test
analysis.
RESULTS
Patterns of gains and losses at chromosome 1 in breast
cancer
We analysed genomic profiles of 30 primary tumours and 30
cancer cell lines by array-CGH using a home-built array covering
chromosome 1 at an average density of one clone/0.85Mb, with
some local variations resulting in higher density locally at 1q. All
cell lines studied, preselected on the basis of classical CGH profiles,
presented gains and/or losses at either 1p or 1q. Array-CGH
profiles were in good concordance with classical CGH data,
confirming the prevalence of losses on the short arm combined
with gains at 1q. However, in contrast to classical CGH data, gains
encompassing the whole 1q were rare, with profiles typically
showing multiple subregions of gains (Figure 1 and Supplementary
Figure S1). Most prevalent gains were at 1q21–q22, 1q23–q24,
1q32 and 1q42–q44, whereas losses were noticeably rare on the
long arm (Figures 1 and 2). On average, tumours and cell lines
presented 1–3 regions of gains per sample (Figure 1).
Our aim was to define the cores of the different regions of CNC
on chromosome 1 and thus, it was important to determine their
boundaries. Correspondingly, we delineated the SROs involved in
either gains or losses on the whole chromosome 1. We overlaid all
the array-CGH profiles and searched for shortest overlaps shared
by at least six independent tumours or cell lines. We defined 19
SROs of gains (one at 1p and 18 at 1q) and 20 SROs of losses (all at
1p) whose sizes ranged from 170kb to 3.2Mb (Figure 1). Precise
locations and BAC content are described in Supplementary Data
(Table S4). However, it must be pointed out that the actual sizes of
these regions of overlap may change according to the resolution of
the array used to define them.
Although, gains were generally of low-to-moderate level, high
magnitude amplifications were observed. Similarly, we observed
high magnitude losses (Figure 1). We were interested to see
whether high magnitude amplifications occurred at recurrent sites
and, accordingly, defined seven peaks of amplification, which all,
except that at 1p12, matched with SROs (Figure 1). This
discrepancy can be explained by the different criteria used to
define peaks of amplification and SROs. Whereas SROs required to
be shared by at least six samples to be retained, peaks of
amplification needed to occur in at least three tumours or cell lines.
Identification of candidate genes involved in CNCs at 1q
Because the relation between genomic gains and increased RNA
expression is well established and linked to a selective advantage
for cancer cells, we concentrated our efforts on the identification of
the genes showing significantly increased expression levels as a
consequence of gains at 1q. To this mean, we analysed RNA
expression profiles of 307 genes located on chromosome 1q in 29
cell lines and 26 tumours using self-made cDNA arrays. We
performed a supervised analysis aiming at selecting genes
differentially expressed in tumours or cell lines presenting a gain.
We formed groups of tumours and cell lines according to their
‘gain’ or ‘no gain’ status in each region. However, based on the 19
SROs, this resulted in a large number of subclasses whose samples
were too small to reach statistical significance. To obviate this
problem we defined larger regions of gains, designated consensus
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Figure 1 Profiles of gains and losses on chromosome 1 in breast cancer. Definition of SROs and events of high magnitude. Grey horizontal lines represent
regions of gains (top) or losses (bottom) observed in each tumour or cell line (minimum two BACs involved with a log2 ratio X0.25 or p 0.25). Shortest
regions of overlap are indicated as bold grey bars with gains above the chromosome ideogram and losses below. Shortest regions of overlap correspond tot h e
smallest overlap shared by at least six tumours or cell lines. Arrow heads indicate events of high magnitude, either peaks of amplification or loss. They
corresponded to events with log2 ratio 40.7 in at least three tumours or cell lines. Code for cell lines 1: BRCAMZ01, 2: BT20, 3: BT474, 4: BT483, 5: CAL51, 6:
EFM19, 7: HCC1187, 8: HCC1395, 9: HCC1428, 10: HCC1937, 11: HCC1954, 12: HCC2218, 13: Hs578T, 14: MCF7Rich, 15: MDAMB157, 16: MDAMB175,
17: MDAMB361, 18: MDAMB435, 19: MDAMB436, 20: MDAMB453, 21: MDAMB468, 22: SKBR3, 23: SKBR7, 24: SUM52, 25: SUM149, 26: SUM185, 27:
T47D, 28: UACC812, 29: ZR751 and 30: ZR7530. Code for primary tumours 1: VA1593, 2: VA4055, 3: VA4380, 4: VA4390, 5: VA4435, 6: VA4956, 7:
VA5033, 8: VA5077, 9: VA5101, 10: VA5410, 11: VA5450, 12: VA6088, 13: VA6190, 14: VA6204, 15: VA6219, 16: VA6277, 17: VA6582, 18: VA6586, 19:
VA6660, 20: VA7079, 21: VA7106, 22: VA7417, 23: VA6052, 24: VA6094, 25: VA6138, 26: VA6143, 27: VA6270, 28: VA6403, 29: VA6603 and 30: VA7072.
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sregions, which encompassed several SROs. To do this, we
determined the occurrence curve for gains at each target clone at
1q. We reasoned that ruptures and low points in the curve
represented the boundaries of the different regions (Figure 2). We
retained only the events whose occurrence exceeded the mean
(horizontal bar on Figure 2) and boundaries were defined by
vertical lines tangential to the occurrence curve. Seven consensus
regions of gains (G1 through G7), ranging from 3.6 to 11Mb and
encompassing two to three SROs on average were defined at 1q
(Table 1 and Figure 2). Gains located between 170 and 180Mb were
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Figure 2 Definition of consensus regions of gain at 1q. Consensus regions were based on the curve of cumulated occurrence of gains (log2.ratio X0.25)
at 1q in 30 cell lines and 30 primary tumours. Low points defined boundaries and high points possible cores. Only regions showing an occurrence exceeding
the mean (9.0) were considered. Plots are based on the Mb positioning of the clones on the array. Hence, clones positioned close to each other may appear
as merged. Consensus regions of gains were designated G1 through G7 and represented as bold grey lines. Short grey lines represent the position of SROs
relative to that consensus regions.
Table 1 Description of consensus regions of gain at 1q
Consensus
segments Genomic positions Size (bp) Cytoband BAC names SRO included
Number of genes
on our array
G1 Start 143154718 5191576 1q21.1 CTD-2122l24 2-3 31
End 148346294 1q21.3 RP11-74C1
G2 Start 150842537 3669729 1q21.3 RP11-73C10 4 36
End 154512266 1q23.1 RP11-91g5
G3 Start 157448999 9571469 1q23.3 RP11-79m15 5-6-7-8 42
End 167020468 1q24.2 RP11-184n12
G4 Start 194594372 7404055 1q31.3 RP11-321M13 11-12-13 33
End 201998427 1q32.1 CTD-2218h7
G5 Start 208699401 5211392 1q32.3 RP11-216f1 14-15 8
End 213910793 1q41 RP11-260a10
G6 Start 223358648 11257879 1q42.12 CTD-2148o23 16-17 19
End 234616527 1q43 RP11-80p14
G7 Start 235845765 8332672 1q43 RP11-130i13 18-19 9
End 244178437 1q44 RP11-172p12
BAC¼bacterial artificial chromosome; SRO¼shortest region of overlap. Consensus regions of gain were defined by the BAC bording them, Mb start corresponds to the 50 end
of the proximal BAC, Mb end to the 30 end of the distal BAC.
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Of the 307 genes studied, 178 genes were located within the
consensus regions of gains defined at 1q. To identify genes whose
expression levels were significantly modified in relation to CNC,
we calculated the DS followed by 1200 random permutations (gain
vs no gain) and our significance threshold for expression
differences was DSX0.32 corresponding to o0.01 false positive.
This resulted in the selection of 30 genes distributed in consensus
regions G1 through G7 (Table 2). Interestingly, we noted that a
number of the selected genes were located in close vicinity to each
other suggesting the existence of local clusters, possibly related to
the existence of core regions of gain.
Candidate gene verification by Q–RT–PCR
In order to confirm expression profiling results, we measured the
RNA expression levels of 28 out of 30 genes by Q–RT–PCR in 25
cell lines typed by array-CGH. The c1orf2 and HNRPU genes could
not be studied because of unsuccessful primer design. In addition
to the 28 genes selected from the cDNA array data, we studied the
recently identified candidate oncogene RAB25 (Cheng et al, 2004),
which is located in consensus region G2, in close vicinity to two of
our candidate genes, MAPBPIP and CCT3 (Table 2). A t-test
analysis revealed that only 5 out of 29 genes showed P-values
¼o0.05, indicative of significant expression differences in
relation to gains. We reasoned that this may be owing to small
sample size (we had to restrict our Q–PCR analysis to the 25 cell
lines because tumour RNAs were no more available) and decided
to consider genes with P-values ¼o0.1. This allowed us to pick
out a total of 11 genes (Table 2). It was, however, noticeable that
the RAB25 gene was not selected in this test, whereas it was, when
we compared mean expression levels in cancer cell lines to that in a
series of five normal breast tissues expression (t-test P-
value¼0.002). We, thus, applied this test to the whole set of
genes which revealed that 21 out of 29 genes were significantly
overexpressed in cancer cell lines compared to normal breast.
DISCUSSION
Chromosome 1 is a prevalent site of numerical anomalies
combining losses on the short arm and gains on the long one in
breast carcinomas (Courjal and Theillet, 1997; Teixeira et al, 2002).
Gains at 1q are found in over 50% of breast tumours. Although
being frequent in high-grade breast cancer, they have been related
to ER-positive cancers (Rennstam et al, 2003; Loo et al, 2004) and
have been suggested to occur early in the natural history of the
disease (Buerger et al, 1999; Malamou-Mitsi et al, 1999). These
particularities fostered our interest in characterising the genomic
regions involved in CNCs and identifying genes at 1q whose
expression was modified in relation to gains.
Array-CGH data presented here confirm chromosomal CGH
results showing the duality on chromosome 1, with the short arm
being mainly involved in losses and the long arm almost
exclusively in gains. Our data clearly indicated the existence of
multiple subregions of losses at 1p and of gains at 1q. In an
attempt to define these subregions with greater precision and
possibly delimitate their cores, we determined the SROs for gains
(19 SROs) and losses (20 SROs) on chromosome 1, whose sizes
ranged from 170kb to over 3Mb. Shortest regions of overlap were
defined according to the classical LOH scheme, in order to narrow
down genetic intervals encompassing candidate genes. Our data
thus suggest that numerical anomalies at chromosome 1, be it
losses or gains, are complex and involve a large number of
subregions and possibly combinations of anomalies.
Although losses at 1p were observed in a sizeable portion of the
tumours and cell lines, gains were notably prevalent. This was in
full agreement with previous chromosomal CGH results by us and
other groups (Courjal and Theillet, 1997; Tirkkonen et al, 1998;
Malamou-Mitsi et al, 1999; Larramendy et al, 2000). Interestingly,
gains at 1q were of low-to-moderate level with a lower prevalence
of amplifications compared to other chromosomes. Furthermore,
no sharp transitions were observed at the boundaries of
amplification peaks at 1q, in contrast to chromosomes 8p or
17q, where such recurrent breakpoint sites were common (Orsetti
et al, 2004; Gelsi-Boyer et al, 2005).
The relation between aberrant gene dosage and gene expression
is well accepted and is best shown in case of CNI. The common
nature of genomic gains (which include DNA amplification) in
breast tumours indicates that it is an effective mechanism of
positive genetic selection in cancer cells (Upender et al, 2004). By
cDNA-array expression profiling, we identified 30 genes whose
RNA expression was significantly increased in relation to genomic
gains. Overexpression in the presence of genomic gain could be
confirmed only for 11 genes by Q–RT–PCR. We suspect that these
numbers may be related to the small size of our sample. We had to
restrict our Q–PCR verification to 25 cell line RNAs, because
tumour RNAs were no more available. We noted that 21 genes
presented significant overexpression when compared to normal
breast, suggesting the involvement of a larger number of genes
within our original selection. It was interesting to see that, to the
exception of PLU-1/JARID1B (Lu et al, 1999), all the genes
identified in our study were newly proposed as candidate cancer
genes. Furthermore, MUC1 (Schroeder et al, 2004), a long known
cell surface marker overexpressed in a sizeable fraction of breast
tumours, and KIF14 (Corson et al, 2005), a recently proposed
candidate at 1q31, presented DSs below the threshold and were
excluded from our selection. Genes selected in our study belong to
rather diverse functional groups, of which three appeared
prevalent. The first corresponded to a broad collection of positive
regulators of cell proliferation. They include PIP5K1A, MAPBPIP,
RAB25A, PCTK3, RAB4 and MPZL1. The second was made of genes
whose products were related to transcriptional regulation or
chromatin remodelling such as USF1, JARID1B, TBX19 or CROC4.
The third included genes involved in cellular trafficking VPS45A,
ARF1, LYST, CCT3 or basic cellular metabolism CA14, ALDH9A1.
Note that RAB25 has also been related to the activation of protein
trafficking between the membrane and the endoplasmic reticulum
(Cheng et al, 2005). Similar functional groups have been observed
in other selections of genes involved in genomic gains or
amplifications, thus indicating the importance of activated
transcription, increased signalling and protein trafficking or
catabolism in cancer. However, 8 out of 24 overexpressed genes
did not belong to any of the above-mentioned functional groups.
Although two genes, PDZK1 and MLLT11, were clearly relevant to
cancer as both have been proposed as a candidate oncogene
in diverse haematological malignancies (Busson-Le Coniat et al,
1999; Inoue et al, 2004; Tse et al, 2004), six were more difficult to
relate to cancer. Three corresponded to genetic determinants of
genetic syndromes (MTMR, DISC1, MTX1) and the three others
bore functions with no obvious link to cancer (NENF, ENSA,
TARBP1).
We were interested to verify the concordance between our
analysis and the recently described ‘Transcriptome Correlation
Map’ (Reyal et al, 2005), which defined groups of collinear genes
showing coordinated expression. Their data set indicated 235
genes presenting a significant Transcriptome Correlation Score
(TCS) at 1q, of which 147 mapped within the region of gains
defined in our work, of which 72 (48%) were located in G1 and G2
(1q21 or 1q22). Genes within consensus regions of gains presented
a significantly higher TCS, thus being in accordance with the
existence of a link between increased expression and copy number
gains at 1q. This was further corroborated by the fact, that 14 out
of 30 (43%) genes selected by DS showed significant TCS, which is
an increase compared to the 55 out of 178 (31%) genes common to
both studies and located in the regions of gains. This suggested an
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sTable 2 Gene expression analysis at 1q and correlation with copy number gain
Consensus
segment
Clone ID
on the chip
Hugo gene
symbol Gene name
Localisation (start–end)
(bp) Cytoband
P-value
1
P-value
2
G1 pdzk1 PDZK1 PDZ domain containing 1 143403500–143439848 1q21.1 0.015
G1 h2bfq HIST2H2BE Histone 2, H2be 146631105–146633327 1q21.2
G1 cra MTMR11 Myotubularin-related protein
11
146675639–146683822 1q21.2 0.09 0.011
G1 vps45b VPS45A Vacuolar protein sorting 45A 146814958–146892599 1q21.2 0.025 0.027
G1 ca14 CA14 Carbonic anhydrase XIV 147005313–147012571 1q21.2 0.019
G1 ensa ENSA Endosulfine alpha 147370158–147377163 1q21.3 0.05 0.025
G1 anxa9 ANXA9 Annexin A9 147729649–147743202 1q21.3
G1 af1q MLLT11 Myeloid/lymphoid or mixed-
lineage leukaemia ; translocated
to, 11
147807778–147816066 1q21.3 0.045
G1 pip5k1a PIP5K1A Phosphatidylinositol-4-
phosphate 5-kinase, type I,
alpha
147897780–147948713 1q21.3 0.09
G2 mtx1 MTX1 Metaxin 1 151952587–151957144 1q22 0.051
G2 c1orf2 C1orf2 Chromosome 1 open reading
frame 2
151994882–152003120 1q22 ND ND
G2 hspc003 MAPBPIP Mitogen-activated protein-
binding protein-interacting
protein
152802478–152806168 1q22 0.076
G2 RAB25 RAB25, member RAS
oncogene family
152808855–152818122 1q22 0.001
G2 cct3 CCT3 Chaperonin containing TCP1,
subunit 3 (gamma)
153056634–153085846 1q22 0.0003
G2 croc4 C1orf61 Chromosome 1 open reading
frame 61
153128056–153153185 1q22 0.075
G3 usf1 USF1 Upstream transcription factor 1 157781513–157787199 1q23.3 0.009 0.007
G3 aldh9 ALDH9A1 Aldehyde dehydrogenase 9
family, member A1
162327485–162364132 1q24.1 0.088 0.022
G3 mpzl1 MPZL1 Myelin protein zero-like 1 164387268–164453994 1q24.2 0.05 0.070
G3 tbx19 TBX19 T-box 19 164946309–164979694 1q24.2 0.027
G4 plu-1 JARID1B Jumonji, AT rich interactive
domain 1B (RBP2-like)
199162987–199245053 1q32.1 0.097 0.095
G4 sox13 SOX13 SRY (sex determining region
Y)-box 13
200442674–200457500 1q32.1
G4 pctk3 PCTK3 PCTAIRE protein kinase 3 201857380–201862760 1q32.1 0.05 0.001
G5 spuf NENF Neuron-derived neurotrophic
factor
209222493–209235935 1q32.3 0.023
G5 esrrg ESRRG Oestrogen-related receptor
gamma
212723109–213309462 1q41
G6 arf1 ARF1 ADP-ribosylation factor 1 224655969–224672451 1q42.13 0.098
G6 rab4 RAB4A RAB4A, member RAS
oncogene family
225806272–225839911 1q42.13 0.020
G6 disc1 DISC1 Disrupted in schizophrenia 1 228235748–228635487 1q42.2 0.001
G6 tarbp1 TARBP1 TAR (HIV) RNA-binding
protein 1
230818923–230906713 1q42.2 0.0009
G6 tbce TBCE Tubulin-specific chaperone e 231749924–231831433 1q42.3
G6 chs1 LYST Lysosomal trafficking regulator 232120934–232326807 1q42.3 0.010
G7 hnrpu HNRPU Heterogeneous nuclear
ribonucleoprotein U
241218474–241229338 1q44 ND ND
ND¼not done and refers to Q–RT–PCR measurements which could not be performed. RNA expression profiles of 307 genes located at 1q were analysed in a total of 29
breast cancer cell lines and 26 primary tumours. Genes presented correspond to the 30 genes selected by DS. Significance threshold was DS40.32 corresponding to o0.01
false positive. Expression levels were quantified by Q–RT–PCR for 28 out of 30 genes (primer design was unsuccessful for c1orf2 and HNRPU). Quantitative PCR primer
sequences are presented in Supplementary Table S2. The recently reported candidate oncogene RAB25, which was not present on our array, was quantified as a positive control.
Quantitative RT–PCR data were analysed for differential expression using two t-test approaches; t-test 1 (noted P-value 1) indicates correlation with copy number gain; t-test 2
(P-value 2) differential expression with normal breast. Two significance thresholds were used; strict P¼o0.05, tolerant P¼o0.1, P-values40.1 were considered as
nonsignificant and only values within the tolerance limit are indicated. Cell lines analysed were: BRCAMZ01, MDAMB175, CAL51, MDAMB435, SKBR7, ZR7530, BT474,
MCF7Rich, HS578T, MDAMB436, SUM149, SUM185, BT20, HCC1187, HCC1428, HCC1937, HCC1954, HCC2218, MDAMB157, MDAMB361, MDAMB468, SKBR3, T47D,
UACC812 and ZR751.
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map in our set of candidate genes at 1q and contrasted to our
previous findings at 8p (Gelsi-Boyer et al, 2005).
Despite their frequent nature, numerical anomalies affecting
chromosome 1 in breast and other cancers have drawn less
attention than deserved. Most studies focussed on specific
subregions or candidate genes. In this work, we characterised at
high-resolution regions recurrently involved in copy number
alterations on chromosome 1 in breast cancer and identified 24
candidate genes overexpressed in regions of gains at 1q. To our
knowledge, this is the first study mapping at high-resolution
regions of loss and gain on the whole length of chromosome 1 and
proposing a series of candidate genes affected by CNCs. Further
work will need to ascertain the true relevance to breast cancer of
these candidate genes. This will require bioclinical and functional
studies. Moreover, as our screen was based on a set of 307 known
genes representing 40–50% of the genes assigned at 1q, our
selection leaves way to the identification of additional candidate
genes.
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